{"id":"W3005971833","doi":"10.1016/j.cgh.2020.02.010","title":"Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis","year":2020,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":79,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"Janssen Pharmaceuticals; Ferring Research Institute; University of California, San Diego; Genentech; Agency for Healthcare Research and Quality; Shire; National Institute of Diabetes and Digestive and Kidney Diseases; MedImmune; Kyowa Hakko Kirin; Arrien Pharmaceuticals; Western University; Covis Pharma; Eli and Edythe Broad Foundation; Crohn's and Colitis Foundation; School of Public Health, University of California Berkeley; Novo Nordisk; Vertex Pharmaceuticals; American College of Gastroenterology; F. Hoffmann-La Roche; Ironwood Pharmaceuticals, Incorporated; Prometheus; Takeda Pharmaceuticals U.S.A.; AbbVie; Johnson and Johnson; Teva Pharmaceutical Industries; Roche; GlaxoSmithKline; Merck; Seres Therapeutics; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb; Biogen; Pfizer; ActoGeniX; Boehringer Ingelheim; Amgen; Gilead Sciences; Celgene","keywords":"Vedolizumab; Medicine; Ulcerative colitis; Logistic regression; Cohort; Internal medicine; Receiver operating characteristic; Cohort study; Gastroenterology; Disease","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01192523,0.001027396,0.00092009,0.003119813,0.0003724326,0.001583868,0.0008883736,0.0006731786,0.001081952],"category_scores_gemma":[0.03031639,0.0003228518,0.00142746,0.001521043,0.0004024883,0.000862346,0.001168743,0.00111052,0.0003410701],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008141211,"about_ca_system_score_gemma":0.001302325,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001713029,"about_ca_topic_score_gemma":0.001863158,"domain_scores_codex":[0.9913162,0.004353016,0.001369108,0.0007344391,0.001825498,0.0004016542],"domain_scores_gemma":[0.9749596,0.01323408,0.005040145,0.00110515,0.00474151,0.0009194901],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.0007450723,0.0003337403,0.9493248,0.00007670567,0.0003444651,0.00006124042,0.00007985085,0.003421603,0.0003352859,0.000196339,0.002007866,0.04307309],"study_design_scores_gemma":[0.0008895737,0.002355355,0.8028016,0.0001885976,0.0004541847,0.0005628225,0.0003073017,0.1835873,0.002560935,0.001178479,0.005023554,0.00009034148],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9761723,0.0008306164,0.01641049,0.0007648192,0.0001450799,0.0007913829,0.002493665,0.00022435,0.002167277],"genre_scores_gemma":[0.9803398,0.0001794658,0.01586905,0.0001666094,0.0000701853,0.0005121619,0.00260705,0.00001465188,0.0002409954],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01192523,"threshold_uncertainty_score":0.06306738,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02660444224199663,"score_gpt":0.302973892684046,"score_spread":0.2763694504420494,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}